Results 41 to 50 of about 42,703 (308)

Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. [PDF]

, 2014
BackgroundIndividuals with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease, partly due to systemic inflammation and endothelial dysfunction.
Del Puerto, Gus, Ganz, Peter, Graf, Jonathan, Grunfeld, Carl, Hsue, Priscilla Y, Imboden, John, Nitta, Elaine, Scherzer, Rebecca, Schnell Heringer, Amanda, Shigenaga, Judy, Wu, Yuaner   +10 more
core   +2 more sources

Chronic hepatitis B in hospitalized rheumatologic patients: problems of screening and reactivation of infection

Современная ревматология, 2023
Objective: to evaluate the completeness of screening for hepatitis B virus (HBV) infection in HBsAg-positive patients admitted to a rheumatology hospital and to follow the history of HBV reactivation/seroversion during antirheumatic therapy.
G. I. Gridneva, E. S. Aronova, B. S. Belov   +2 more
doaj   +1 more source

Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study [PDF]

, 2017
[Abstract] The ARCO study (Study on Adherence of Rheumatoid Arthritis patients to SubCutaneous and Oral Drugs), a multicenter, non-interventional retrospective study, was primarily designed to assess the percentage of patients [aged ≥18 years with an ...
Alegre-Sancho, Juan J., Calvo-Alén, Jaime, Carmona, Loreto, Cea-Calvo, Luis, De-Toro, Javier, Escudero, Alejandro, Marras, Carlos, Mestre, Yvonne, Monteagudo, Indalecio, Ortiz, Ana, Raya, Enrique, Salvador, Georgina   +11 more
core   +2 more sources

Repeat prescribing of medications: a system-centred risk management model for primary care organisations [PDF]

, 2017
Rationale, aims and objectives: Reducing preventable harm from repeat medication prescriptions is a patient safety priority worldwide. In the United Kingdom, repeat prescriptions items issued has doubled in the last 20 years from 5.8 to 13.3 items ...
Bartlett, Stephen, Bowie, Paul, Dinwoodie, Mark, Man, Shu Ling, Price, Julie, Taylor, Kate   +5 more
core   +1 more source

Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing [PDF]

, 2020
Both inflammatory diseases like rheumatoid arthritis (RA) and anti-inflammatory treatment of RA with glucocorticoids (GCs) or non-steroidal anti-inflammatory drugs (NSAIDs) negatively influence bone metabolism and fracture healing.
Brinkman, Antonia Clara Katharina, Burmester, Gerd-Rüdiger, Buttgereit, Frank, Damerau, Alexandra, Diesing, Karoline, Gaber, Timo, Hoff, Paula, Lang, Annemarie, Ohrndorf, Sarah, Pfeiffenberger, Moritz, Pienczikowski, Justyna   +10 more
core   +1 more source

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain [PDF]

Farmacia Hospitalaria, 2014
Objective: To compare the cost of treating rheumatoid arthritis patients that have failed an initial treatment with methotrexate, with subcutaneous aba - tacept versus other first-line biologic disease-modifying antirheumatic drugs. Method: Subcutaneous
R. Ariza, A. van Walsem, C. Canal, C. Roldán, L. Betegón, I. Oyagüez, K. Janssen   +6 more
doaj   +1 more source

Hepatic toxicity of antirheumatic drugs

Cleveland Clinic Journal of Medicine, 1993
Many of the diverse group of pharmacologic agents available for the treatment of rheumatic diseases have the potential to cause serious hepatotoxicity.To identify factors associated with drug-induced hepatotoxicity in rheumatic disease.While mild elevations in plasma transaminase concentrations are associated with almost all nonsteroidal anti ...
D. G. Vidt, A. Bakst, E. P. Brass
openaire   +3 more sources

Silymarin Supplementation in Active Rheumatoid Arthritis: Outcomes of a Pilot Randomized Controlled Clinical Study

Medicina
Background and Objectives: Coadministration of natural products to enhance the potency of conventional antirheumatic treatment is of high interest.
Georgeta Stefanovici Zugravu, Carmen Pintilescu, Carmen-Marinela Cumpat, Sorin Dan Miron, Anca Miron   +4 more
doaj   +1 more source

Immunodeficiency and autoimmunity during biological disease-modifying antirheumatic drug therapy

Rheumatology, 2019
Biological disease-modifying antirheumatic drugs target specific components of the immune response related to pathogenesis of autoimmune and inflammatory diseases.
Anna Czekalska, Dominik Majewski, Mariusz Puszczewicz   +2 more
doaj   +1 more source

Shared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases

Современная ревматология, 2022
The review is devoted to the relationship between the pathogenetic mechanisms of coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases (IRD).
K. S. Rutskaya-Moroshan, S. T. Abisheva, A. M. Lila   +2 more
doaj   +1 more source